PHIO PHARMACEUTICALS CORP. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
PHIO PHARMACEUTICALS CORP. (PHIO) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $1.14 per share for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2025-03-31
- PHIO PHARMACEUTICALS CORP. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2019-03-31 was $0.29, a 91.34% decline year-over-year.
- PHIO PHARMACEUTICALS CORP. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2018-06-30 was $1.72, a 63.40% decline year-over-year.
- PHIO PHARMACEUTICALS CORP. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2018-03-31 was $3.35, a 34.31% decline year-over-year.
- PHIO PHARMACEUTICALS CORP. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2017-09-30 was $4.90, a 115.86% increase year-over-year.
- PHIO PHARMACEUTICALS CORP. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $1.14.
- PHIO PHARMACEUTICALS CORP. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2017 was $4.90, a 77.21% decline from fiscal 2016.
- PHIO PHARMACEUTICALS CORP. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2016 was $21.50, a 424.39% increase from fiscal 2015.
- PHIO PHARMACEUTICALS CORP. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2015 was $4.10, a 68.72% increase from fiscal 2014.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2023-12-31 | $1.14 10-K · filed 2025-03-31 | |||||||
| 2019-03-31 | $0.29 10-Q · filed 2019-05-14 | |||||||
| 2018-06-30 | $1.72 10-Q · filed 2018-08-14 | $2.80 10-Q · filed 2018-08-14 | ||||||
| 2018-03-31 | $3.35 10-Q · filed 2019-05-14 | |||||||
| 2017-12-31 | $4.90 10-K · filed 2018-03-26 | |||||||
| 2017-09-30 | $4.90 10-Q/A · filed 2018-03-26 | $0.49 10-Q · filed 2017-11-08 | $4.90 10-Q/A · filed 2018-03-26 | $0.49 10-Q · filed 2017-11-08 | ||||
| 2017-06-30 | $4.70 10-Q · filed 2018-08-14 | $0.47 10-Q · filed 2017-08-10 | $4.90 10-Q · filed 2018-08-14 | $0.49 10-Q · filed 2017-08-10 | ||||
| 2017-03-31 | $5.10 10-Q · filed 2018-05-10 | $0.51 10-Q · filed 2017-05-11 | ||||||
| 2016-12-31 | $21.50 10-K · filed 2018-03-26 | $2.15 10-K · filed 2017-03-30 | ||||||
| 2016-09-30 | $2.27 10-Q · filed 2016-11-10 | $21.50 10-Q/A · filed 2018-03-26 | $2.15 10-Q · filed 2016-11-10 | |||||
| 2016-06-30 | $21.50 10-Q/A · filed 2018-03-26 | $2.15 10-Q · filed 2016-08-11 | ||||||
| 2016-03-31 | $22.00 10-Q/A · filed 2018-03-26 | $2.20 10-Q · filed 2016-05-12 | ||||||
| 2015-12-31 | $4.10 10-K · filed 2017-03-30 | $0.41 10-K · filed 2016-03-30 | ||||||
| 2015-09-30 | $4.40 10-Q · filed 2016-11-10 | $0.44 10-Q · filed 2015-11-12 | $4.10 10-Q · filed 2016-11-10 | $0.41 10-Q · filed 2015-11-12 | ||||
| 2015-06-30 | $2.80 10-Q · filed 2016-08-11 | $0.28 10-Q · filed 2015-08-12 | $4.10 10-Q · filed 2016-08-11 | $0.41 10-Q · filed 2015-08-12 | ||||
| 2015-03-31 | $8.88 10-Q · filed 2016-05-12 | $0.88 10-Q · filed 2015-05-13 | ||||||
| 2014-12-31 | $2.43 10-K · filed 2016-03-30 | |||||||
| 2014-09-30 | $2.71 10-Q · filed 2015-11-12 | $2.46 10-Q · filed 2015-11-12 | ||||||
| 2014-06-30 | $2.26 10-Q · filed 2015-08-12 | $2.42 10-Q · filed 2015-08-12 | ||||||
| 2014-03-31 | $4.62 10-Q · filed 2015-05-13 | |||||||
| 2013-12-31 | $4.05 10-K · filed 2015-03-30 | |||||||
| 2013-09-30 | $4.24 10-Q · filed 2014-11-13 | $4.05 10-Q · filed 2014-11-13 | ||||||
| 2013-06-30 | $3.90 10-Q · filed 2014-08-14 | $3.90 10-Q · filed 2014-08-14 | ||||||
| 2012-12-31 | $2.10 10-K · filed 2014-03-28 | $0.07 10-K · filed 2013-03-29 | ||||||
| 2012-09-30 | $4.20 10-Q · filed 2013-11-14 | $0.14 10-Q · filed 2012-11-13 | $2.10 10-Q · filed 2013-11-14 | $0.07 10-Q · filed 2012-11-13 | ||||
| 2012-06-30 | $1.75 10-Q · filed 2013-08-14 | $0.07 10-Q · filed 2012-08-14 | $1.75 10-Q · filed 2013-08-14 | $0.07 10-Q · filed 2012-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |